DBV Technologies | DBVT - Net Income


DBV Technologies reported $-33.16M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
Acadia Pharmaceuticals USD 71.78M 45.11M Sep/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amarin USD -7.74M 6.4M Sep/2025
BioCryst Pharmaceuticals USD -88.88M 74.85M Dec/2024
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
DBV Technologies USD -33.16M 8.71M Sep/2025
Esperion Therapeutics USD -29.52M 32.4M Sep/2024
Galectin Therapeutics USD -12.37M 880K Jun/2024
Halozyme Therapeutics USD -141.59M 316.82M Dec/2025
Incyte USD 299.28M 124.89M Dec/2025
Insmed USD -328.48M 41.54M Dec/2025
Ionis Pharmaceuticals USD -128.61M 252.16M Sep/2025
Neurocrine Biosciences USD 209.5M 102M Sep/2025
PTC Therapeutics USD -134.96M 150.86M Dec/2025
Sarepta Therapeutics USD -179.95M 376.84M Sep/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
United Therapeutics USD 338.7M 29.2M Sep/2025